Live: Will FedEx Crush Q4 Earnings Tonight After the Market Closes?
WST Q4 2025 Earnings
Reported Feb 12, 2026 at 7:21 AM ET · SEC Source
Q4 25 EPS
$2.04
BEAT +11.54%
Est. $1.83
Q4 25 Revenue
$805.0M
BEAT +1.28%
Est. $794.8M
vs S&P Since Q4 25
+39.4%
BEATING MARKET
WST +47.0% vs S&P +7.6%
Full Year 2025 Results
FY 25 EPS
$7.29
FY 25 Revenue
$3.07B
Market Reaction
Did WST Beat Earnings? Q4 2025 Results
West Pharmaceutical Services closed out fiscal 2025 on a strong note, posting Q4 adjusted diluted EPS of $2.04, beating the $1.83 consensus estimate by 11.48%, as revenue climbed 7.5% year-over-year to $805.00 million. The standout driver was a 15.1%… Read more West Pharmaceutical Services closed out fiscal 2025 on a strong note, posting Q4 adjusted diluted EPS of $2.04, beating the $1.83 consensus estimate by 11.48%, as revenue climbed 7.5% year-over-year to $805.00 million. The standout driver was a 15.1% organic surge in High-Value Product Components, fueled by demand for Westar and Envision products, while GLP-1-related revenues proved a meaningful contributor, with elastomers alone accounting for 10% of total company sales in the quarter. Gross margin expanded 130 basis points to 37.8%, and adjusted diluted EPS grew 12.1% versus the prior-year period. For the full year, free cash flow jumped 69.6% to $468.90 million, a performance strong enough to support a newly authorized $1 billion share repurchase program alongside a quarterly dividend of $0.22 per share. Looking ahead, management guided fiscal 2026 net sales of $3.21 billion to $3.27 billion and adjusted EPS of $7.85 to $8.20, representing earnings growth of 7.7% to 12.5%, with Contract Manufacturing margins expected to recover to historical levels as early as Q1 2026.
Key Takeaways
- • Double-digit organic growth in HVP Components driven by Westar and Envision products
- • GLP-1 elastomers represented 10% of total company revenues in Q4
- • GLP-1 Contract Manufacturing revenues represented 7% of total company revenues in Q4
- • Biologics market group accounted for 42% of Q4 revenue
- • Favorable foreign currency translation contributed 4.2 percentage points to Q4 revenue growth
- • EMEA region led geographic growth at 14.6% year-over-year
WST YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
WST Revenue by Segment
With YoY comparisons, source: SEC Filings
WST Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our strong finish to 2025 was a result of the team's relentless execution of our growth strategy. Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders.”
— Eric M. Green, Q4 2025 Earnings Press Release
WST Earnings Trends
WST vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
WST EPS Trend
Earnings per share: estimate vs actual
WST Revenue Trend
Quarterly revenue: estimate vs actual
WST Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $1.68 | $2.13 | +27.07% | $844.9M | +8.41% |
| Q4 25 BEAT FY | $1.83 | $2.04 | +11.54% | $805.0M | +1.28% |
| FY Full Year | — | $7.29 | — | $3.07B | — |
| Q3 25 BEAT | $1.69 | $1.96 | +16.31% | $804.6M | +2.15% |
| Q2 25 BEAT | $1.51 | $1.84 | +21.98% | $766.5M | +5.55% |